SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI
Abstract Background Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function. Methods and results In total, 333 non-diabetes patients with...
Main Authors: | Yulin Yang, Xiaolin Wang, Yongchao Wang, Hao Xu, Jian Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12872-023-03353-1 |
Similar Items
-
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01) -
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
by: Matteo Pagnesi, et al.
Published: (2022-01-01) -
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
by: Ghader Mohammadnezhad, et al.
Published: (2022-12-01) -
Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
by: Qianyu Fu, et al.
Published: (2023-11-01) -
Prevalence of Prediabetes and Newly diagnosed Diabetes in Patients with HFpEF and HFrEF
by: Ahmad ELSharawy, et al.
Published: (2024-01-01)